A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study

Trial Profile

A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs VAX 125 (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors VaxInnate
  • Most Recent Events

    • 17 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2009 Results reported in a VaxInnate media release. Phase I results will also be presented at the National Foundation for Infectious Diseases' Twelfth Annual Conference on Vaccine Research.
    • 04 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top